<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lck/yes-related novel (Lyn) tyrosine kinase overexpression has been suggested to be important for leukaemic cell growth making it an attractive target for therapy </plain></SENT>
<SENT sid="1" pm="."><plain>By contrast, Lyn deficiency was shown to be responsible for a phenotype resembling myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (MPN) in mice </plain></SENT>
<SENT sid="2" pm="."><plain>We aimed to shed more light on Lyn's role in haematological <z:hpo ids='HP_0002664'>neoplasm</z:hpo> and systematically investigated Lyn expression in MPN, <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> subtypes (n = 236) </plain></SENT>
<SENT sid="3" pm="."><plain>On top, B-cell <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (B-CLL) and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> significantly overexpressed Lyn when compared to de novo <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, de novo <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and Philadelphia-chromosome-negative myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (p &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>Most of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> subtypes showed a notable down-regulation of Lyn <z:chebi fb="2" ids="33699">mRNA</z:chebi> but anyhow individual cases were labelled for the active form of Lyn protein </plain></SENT>
<SENT sid="5" pm="."><plain>Intriguingly, <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> evolved in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> revealed almost undetectable Lyn </plain></SENT>
<SENT sid="6" pm="."><plain>Overexpression of Lyn in B-CLL was associated with a significant down-regulation of microRNA-337-5p suggesting that aberrant expression of this particular microRNA could be involved in post-transcriptional control of Lyn <z:chebi fb="2" ids="33699">mRNA</z:chebi> fate </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that tyrosine kinase Lyn contributes to the malignant phenotype in certain <z:mpath ids='MPATH_336'>leukaemia</z:mpath> subtypes and therefore attracts targeted therapy </plain></SENT>
</text></document>